
Parkinson Cell Therapy ANPD001 Generates Promising Early-Stage Phase 1/2 Data
New findings from 3 individuals in a first-in-human, phase 1/2 trial (NCT0634406) showed that treatment with ANPD001 (Aspen Neuroscience), an investigational autologous induced pluripotent stem cell (iPSC)-derived therapy, was safe and resulted in …